Jacobs Levy Equity Management Inc. Grows Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Jacobs Levy Equity Management Inc. increased its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 9.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 753,845 shares of the biotechnology company’s stock after purchasing an additional 63,437 shares during the period. Jacobs Levy Equity Management Inc. owned approximately 0.79% of Sarepta Therapeutics worth $94,148,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in SRPT. Tidal Investments LLC increased its stake in Sarepta Therapeutics by 8.5% during the 1st quarter. Tidal Investments LLC now owns 2,902 shares of the biotechnology company’s stock valued at $376,000 after purchasing an additional 228 shares in the last quarter. Comerica Bank raised its position in shares of Sarepta Therapeutics by 489.4% in the first quarter. Comerica Bank now owns 3,336 shares of the biotechnology company’s stock valued at $432,000 after buying an additional 2,770 shares during the last quarter. Cetera Investment Advisers raised its position in shares of Sarepta Therapeutics by 27.6% in the first quarter. Cetera Investment Advisers now owns 11,991 shares of the biotechnology company’s stock valued at $1,552,000 after buying an additional 2,590 shares during the last quarter. GAMMA Investing LLC increased its position in Sarepta Therapeutics by 91.9% during the second quarter. GAMMA Investing LLC now owns 618 shares of the biotechnology company’s stock worth $98,000 after purchasing an additional 296 shares during the last quarter. Finally, CWM LLC increased its position in Sarepta Therapeutics by 30.4% during the second quarter. CWM LLC now owns 871 shares of the biotechnology company’s stock worth $138,000 after purchasing an additional 203 shares during the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

SRPT has been the subject of several analyst reports. UBS Group boosted their price target on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Piper Sandler reduced their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. Needham & Company LLC cut their price target on Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating for the company in a research note on Wednesday, November 27th. StockNews.com cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Finally, Jefferies Financial Group started coverage on Sarepta Therapeutics in a report on Monday, October 21st. They issued a “buy” rating and a $165.00 price target for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $175.55.

Sarepta Therapeutics Trading Down 4.0 %

Shares of SRPT stock opened at $127.95 on Tuesday. The company’s fifty day simple moving average is $122.50 and its two-hundred day simple moving average is $131.48. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics, Inc. has a 1 year low of $83.97 and a 1 year high of $173.25. The stock has a market capitalization of $12.22 billion, a price-to-earnings ratio of 102.36 and a beta of 0.77.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.